Background: Injectable opioid agonist treatment (iOAT) is an emerging evidence-based
option in the continuum of care for opioid use disorder in parts of Canada. Our study …

Background Addressing inadequacies in the implementation of existing evidence-based
approaches into practice, such as injectable opioid agonist treatment (iOAT), is imperative …

Background To support public health measures during the COVID-19 pandemic, oral opioid
agonist treatment (OAT) take-home doses were expanded in Western countries with positive …

Background People living in rural and remote communities in Canada are often
disproportionately impacted by opioid use disorder. When compared to urban centres, rural …

Background The opioid epidemic remains a public health crisis and most people with opioid
use disorder (OUD) do not receive effective treatment. The emergency department (ED) can …

Background Injectable opioid agonist treatment (iOAT) is an effective option to support
people living with opioid use disorder (OUD) who have not sufficiently benefitted from oral …

Background Rural and smaller urban settings in Canada are disproportionately impacted by
the overdose crisis, highlighting the need for novel public health interventions within these …

Background A cascade of care framework has been proposed to identify and address
implementation gaps in addiction medicine. Using this framework, we characterized …

BackgroundOpioid use disorder is a major public health crisis, and evidence suggests ways
of better serving patients who live with opioid use disorder in the emergency department …

Background Injectable opioid agonist treatment (iOAT) is effective for opioid use disorder
(OUD), yet little is known about client preferences for accessing iOAT (eg, with …